10-QPeriod: Q2 FY2023

BIOGEN INC. Quarterly Report for Q2 Ended Jun 30, 2023

Filed July 25, 2023For Securities:BIIB

Summary

Biogen Inc. reported a decrease in total revenue for the second quarter of 2023, primarily driven by a significant decline in Multiple Sclerosis (MS) product revenue due to increased generic competition for TECFIDERA and market shifts away from Interferon therapies. While Spinal Muscular Atrophy (SMA) revenue saw a slight increase, the overall product revenue was down 10.2% year-over-year. This revenue decline, coupled with an increase in cost of sales and R&D expenses, led to a substantial decrease in net income and diluted earnings per share compared to the prior year period. However, the company's cash position remains strong, with a significant increase in cash, cash equivalents, and marketable securities, bolstered by a substantial payment received from the Samsung Bioepis sale. The company also announced a new "Fit for Growth" program aimed at significant operating expense savings.

Financial Highlights

49 data points
Beta

Revenue

$2.46B

75.9% Gross Margin

Net Income

$591.60M

24.1% Net Margin

EPS (Diluted)

$4.07

Total Assets

$25.16B

Cash & Equivalents

$2.62B

Free Cash Flow

$416.00M

Financial Statements
Beta
Revenue$2.46B
Cost of Revenue$592.70M
Gross Profit$1.86B
SG&A Expenses$548.00M
Operating Expenses$1.75B
Interest Expense$49.10M
Net Income$591.60M
EPS (Basic)$4.09
EPS (Diluted)$4.07
Shares Outstanding (Basic)144.70M
Shares Outstanding (Diluted)145.50M

Key Highlights

  • 1Total revenue decreased by 5.1% to $2,456.0 million in Q2 2023 compared to Q2 2022, largely due to a 10.2% decrease in product revenue.
  • 2Multiple Sclerosis (MS) revenue declined by 15.2% year-over-year, primarily driven by generic competition for TECFIDERA and a shift to higher-efficacy therapies for Interferon products.
  • 3Spinal Muscular Atrophy (SMA) revenue saw a modest 1.4% increase due to higher SPINRAZA sales volumes and pricing in the U.S.
  • 4Research and Development (R&D) expenses increased by 10.5% for the quarter, driven by investments in LEQEMBI, litifilimab, and BIIB800, as well as close-out costs.
  • 5Net income attributable to Biogen Inc. decreased significantly by 44.2% to $591.6 million in Q2 2023, leading to a 43.8% decrease in diluted earnings per share to $4.07.
  • 6The company generated $942.3 million in net cash flow from operating activities for the first six months of 2023.
  • 7Biogen announced a new 'Fit for Growth' program targeting $1.0 billion in gross operating expense savings by 2025, with a net headcount reduction of approximately 1,000 employees.

Frequently Asked Questions

The primary driver for the decrease in Biogen's revenue is the significant decline in Multiple Sclerosis (MS) product revenue, particularly for TECFIDERA, due to the entry of generic competitors in key markets. Additionally, a shift in patient preference towards newer, more effective therapies has impacted Interferon-based MS products.

Biogen recognized a reduction of $20.7 million in revenue for the three months ended June 30, 2023, related to its net profit share in the LEQEMBI collaboration. The company anticipates continued losses on this profit share in 2023 as commercial expenses are expected to exceed initial revenue, despite LEQEMBI receiving traditional FDA approval in July 2023.

The 'Fit for Growth' program is a new initiative announced by Biogen to achieve approximately $1.0 billion in gross operating expense savings by 2025. Of this, $300.0 million is planned to be reinvested into product launches and R&D, resulting in an estimated $700.0 million in net savings. The program is expected to involve a reduction of approximately 1,000 employees.

Biogen's cash, cash equivalents, and marketable securities increased to approximately $7.3 billion as of June 30, 2023, up from $5.6 billion at the end of 2022. This increase was supported by cash flow from operations and a substantial payment received from the sale of its equity interest in Samsung Bioepis. The company believes its current financial resources are sufficient to meet its operating and capital expenditure needs for the foreseeable future.